Oxford BioMedica PLC (OXBDF)

[marcusl2]

The start of Kymriah expanding. I think that it will be a big earner eventually.

HTTPS://asia.nikkei.com/Business/Companies/Novartis-seeks-outcomes-based-pricing-in-Japan-for-cancer-drug

"The time has come to rethink Japan's drug-pricing system," said Ataru Igarashi, associate professor at the University of Tokyo's Graduate School of Pharmaceutical Sciences.

Novartis looks to apply in the first half of 2018 to have national insurance pay for Kymriah. Many drugs treating rare diseases take between seven and nine months to receive approval from the health ministry and are priced two months after that. The final price will likely depend on whether Novartis can apply outcomes-based pricing. If all goes smoothly, Kymriah could hit the Japanese market as early as next year.